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INTRODUCTION
Tuberculosis (TB) infections with Mycobacterium tuberculosis 
(M. tb) remain a leading cause of ill health and death despite 
global efforts to reduce the burden of TB.1-3 The worldwide in-
cidence of TB has continued to decline from 170 in 2000 to 130 
in 2018 per 100000 people, and the absolute number of TB 
deaths has fallen by 27% among human immunodeficiency vi-
rus–negative individuals.4 However, successful treatment out-
come rates for multidrug-resistant (MDR) TB has reached only 
56% as of 2018. Therefore, early and accurate diagnosis, as 
well as prompt initiation of treatment, are priorities for con-
trolling TB.4,5 
The burden of new TB cases in Asia accounts for 62% of all TB 
cases worldwide,4 and three countries, including India (27%), 
China (9%), and Indonesia (8%), in this region contributed to 
almost half of the global total number of cases in 2018.4 The M. 
tb Beijing lineage has been reported throughout the region, 
with frequent genetic variations in the genome. It has been 
linked with an increase in MDR-TB with highly transmissible 
and virulent features.6,7 Mice infected with the Beijing M299 
strain have been found to show irreversible necrotic lung le-
sions with enhanced inflammatory responses.8 Thus, under-
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standing the characteristics of the Beijing stain is an essential 
requirement for improving the state of epidemiological control. 
In South Korea, TB is still a major public health concern, with 
an incidence of 66 cases per 100000 populations, and MDR/ri-
fampicin-resistant-TB in new cases was estimated to be 3.2%.9 
The incidence rate of TB has been declining in past years, al-
though transmission has been still ongoing within communi-
ties, such as schools or workplaces.10 About 80% of clinical 
isolates of pulmonary TB patients have been reported to carry 
Beijing genotype,11-13 and Beijing/K strains were firstly desig-
nated as the causative factor of a major cluster of high school 
TB outbreaks.14 Beijing/K strains are also frequently isolated 
from patients with drug resistance in South Korea.12 The Bei-
jing/K strain is hyper-virulent and rapidly replicates with severe 
pathologies at early time points during infection, compared with 
M. tb H37Rv in mice.15 Whole-genome sequencing of the Bei-
jing/K strain has revealed a 5.7-kb insertion region in the ge-
nome, which is disrupted by IS6110 insertion, unlike the H37Rv 
strain.16 Within the insertion, MTBK_24820 (GenBank accession 
no. AIB49026.1) was predicted as a member of the proline-pro-
line-glutamic acid (PPE) family which is orthologous to the 
PPE39 protein of M. tb H37Rv.17 MTBK_24790 (GenBank acces-
sion no. AIB49023.1) and MTBK_24800 (Genbank accession 
no. AIB49024.1) were also identified as ESAT-6-like proteins.18-20 
The three proteins are arranged in a row within the cluster, indi-
cating that Esx family proteins containing the PPE family may 
play an immune-pathogenic role in hosts infected with the Bei-
jing/K strain. 
There is no gold standard for the diagnosis of latent tubercu-
losis infection (LTBI), although the following two methods are 
currently used in parallel: tuberculin skin test and interferon 
(IFN)-γ release assay (IGRA). Tuberculin skin test has been a 
recognized a conventional immunodiagnostic test for the last 
century, but its major drawback is a low specificity in BCG-vac-
cinated individuals and nontuberculous mycobacteria-sensi-
tized persons, resulting in false-positive reactions.21 A recently 
developed IGRA, the QuantiFERON®-TB Gold In-Tube test 
(QFT-GIT; Qiagen, Hilden, Germany) offers superior sensitiv-
ity and specificity in active TB patients, compared with the tu-
berculin skin test.22,23 However, the QFT-GIT test cannot reflect 
the accurate status of disease progression with repeated con-
versions or reversions and has a limitation in that children un-
der 4 years old yield indeterminate results.24-26 These shortcom-
ings suggest an urgent requirement for improved methods 
using additional antigens or biomarkers in early diagnosis of M. 
tb infection for successful TB control. 
In this study, we aimed to determine immune signatures that 
may serve as potential biomarkers for identifying M. tb infec-
tion, focusing on new antigen candidates for future diagnostics 
or a vaccine component. We previously demonstrated the pro-
tective efficacy of M. tb Beijing/K strain-derived PPE protein 
(MTBK_24820) in mice:17 mice infected with MTBK_24820 
showed reduced bacterial loads and enhanced multifunction-
al T-cell activity, which indicate that the MTBK_24820 could 
potentially be used as a future vaccine component.17 Here, we 
evaluated 17 different cytokines and chemokines produced by 
type 1 or 2 T helper cells. The diagnostic potential of immune 
responses to MTBK_24820 was assessed in a population with 
BCG vaccination. 
MATERIALS AND METHODS
Enrolment and characteristics of study participants
A total of 52 active TB patients and 96 healthy controls were 
enrolled between October 2013 and March 2015 at Ajou Uni-
versity Hospital (Fig. 1). The diagnosis of active pulmonary TB 
was made when M. tb was identified in the culture of a clinical 
specimen, or in the case of negative culture results, when sug-
gestive clinical and radiologic features were reinforced by re-
sponse to anti-TB therapy. About 29% (15 of 52) of the patients 
showed positive results of acid-fast bacilli (AFB) staining at ear-
ly diagnosis, whereas M. tb was identified in about 77% (40 of 
52) of patients by culture. Beijing or Beijing/K genotype was 
confirmed in 68% or 50% of the clinical isolates tested, from 
patients with AFB positive or culture positive results.19 Seven 
patients had extrapulmonary TB, such as pleural effusion, cer-
vical lymphadenopathy, colitis, and meningitis. TB lymphadeni-
tis was diagnosed by the presence of M. tb or by observing typi-
cal pathologic findings in a lymph node tissue specimen and 
demonstration of an appropriate response to anti-TB medica-
tion. TB pleural effusion was diagnosed by the presence of M. 
tb or by observation of typical pathologic findings in pleural tis-
sues or compatible findings in cellular and biochemical analy-
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Fig. 1. Schematic diagram of the study design and subject enrolment. The 
study participants included 52 active TB patients, 31 latent TB infected 
subjects, and 65 non-infected healthy controls (gray boxes). Whole blood 
obtained from each subject was stimulated with M. tb Beijing/K-derived 
antigens, M. tb PPD, and HBHA, respectively. Potential biomarkers (i.e., 
IFN-γ, IL-6, CXCL10, TNF-α, and IFN-α) for TB were selected based on the 
immune signature through multiplex bead arrays. TB, tuberculosis; M. tb, 
Mycobacterium tuberculosis; QFT-GIT, QuantiFERON®-TB Gold In-Tube; 
LTBI, latent TB infection; HC, healthy control. AFB, acid-fast bacilli; PPD, 
purified protein derivatives; HBHA, heparin-binding haemagglutinin; IFN, 
interferon; IL, interleukin; CXCL10, C-X-C motif chemokine; TNF, tumor ne-
crosis factor.
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ses of pleural fluid, with an accompanying appropriate response 
to anti-TB medication. The diagnosis of meningeal TB was 
supported by cerebrospinal fluid biochemical findings. Chest 
computed tomography was performed in all TB patients and 
was utilized as an adjunctive tool for diagnosis of TB, especially 
in cases with negative culture results. The diagnosis of active TB 
was initially made by the physician in charge of the patients and 
was subsequently verified by the principal investigators. After 
completion of the enrollment, the patients were continuously 
followed up until August 2019 (at least 4.5 years), and finally, 
the diagnosis was independently reviewed and verified by one 
radiologist and two other respiratory medicine specialists, af-
ter which a final decision was made by consensus. 
BCG scars were confirmed in most patients (49 of 52). The 
mean age of the patients was 43 years, and age-matched healthy 
controls were recruited from volunteers via routine health ex-
aminations performed at the same hospital. The healthy con-
trol group was examined for M. tb infection, and individuals 
with LTBI (n=31) and naïve controls (n=65) were differentiat-
ed according to the outcome of QFT-GIT testing (Fig. 1). Indi-
viduals with immunosuppressive conditions who had cancer, 
diabetes, human immunodeficiency virus infection, or chron-
ic renal failure were excluded. Written informed consent was 
obtained from all of the study participants, and all experiments 
were performed in accordance with relevant guidelines. The 
study protocol was approved by the Ajou University Hospital 
Ethics Review Committee (AJIRB-GEN-GEN-13-025, AJIRB-
MED-SMP-12-068). 
Preparation of blood samples 
For QFT-GIT assay, 1 mL of blood was collected into each of 
three QFT-IT tubes (Qiagen, Hilden, Germany) precoated with 
saline (Nil) or an M. tb-specific peptide cocktail composed of 
ESAT-6, CFP-10, TB7.7 (Rv2654), and phytohemagglutinin 
(PHA; Mitogen). The tubes were incubated upright at 37°C for 
24 h, and harvested plasma samples were frozen at -80°C until 
analysis. For diluted whole-blood assay, blood was collected 
in heparinized tubes (BD Vacutainer, Plymouth, UK) and was 
diluted with RPMI media (1 in 5; Invitrogen, Grand Island, 
NY, USA). 
Preparation of antigens
Recombinant MTBK_24820 protein was prepared as previous-
ly described.17 MTBK_24820 was constructed using a pYUB1062 
vector with NdeI and HindIII (New England Biolabs, Ipswich, 
MA, USA) sites. The constructed plasmid was overexpressed 
in Escherichia coli by the addition of 1 mM isopropyl-b-d-thio-
galactopyranoside (BioWorld, Dublin, OH, USA). The protein 
was purified using Ni-NTA agarose resin (Qiagen, Venlo, Neth-
erlands) and MonoQ anion exchange columns on an ÄKTA-
FPLC system (GE Healthcare Biosciences, Pittsburgh, PA, 
USA) (Supplementary Fig. 1, only online). Protein concentra-
tions were measured using a BCA assay (Thermo Fisher Sci-
entific, Inc., Rockford, IL, USA) and stored at -80°C until ready 
for use.
QFT-GIT testing
QFT-GIT assays were performed with harvested plasma ac-
cording to the manufacturer’s instructions (Qiagen). Briefly, 
50 μL of conjugate and plasma, respectively, were added to a 
QFT-GIT enzyme-linked immunosorbent assay (ELISA) plate 
and incubated for 2 h at room temperature. After washing the 
plate six times, 100 μL of substrate solution was added and in-
cubated. Absorbance was measured at 450 nm using a Versa-
Max ELISA reader (Molecular Devices, Sunnyvale, CA, USA), 
and the concentration of IFN-γ was calculated and interpreted 
by the analysis on the QuantiFERON®-TB Gold analysis soft-
ware.
Diluted whole blood assays
Diluted whole blood assays were conducted as previously de-
scribed using MTBK_24820 as the M. tb Beijing/K-specific an-
tigen.27 The protein antigen was separately purified and mixed 
in a tube for whole blood assay experiments. PHA and M. tb 
purified protein derivatives (PPD) were used as positive con-
trols for immunocompetence and reactivity to mycobacterial 
antigens, respectively. RPMI1640 medium was used as a neg-
ative control. Diluted blood was added into each well includ-
ing antigens at 5 μg/mL. After 6 days of incubation at 37°C, the 
culture supernatant was harvested, and cytokine/chemokine 
responses were determined by multiplex bead array.
Multiplex bead arrays
Cytometric bead array was performed according to the manu-
facturer’s instructions (BD Biosciences, San Jose, CA, USA) as 
described in a previous study.28 Harvested culture superna-
tant was analyzed with the following 17 different cytokines 
and chemokines: interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-
9, IL-10, IL-12p70, IL-13, IL-17A, IL-22, IFN-α, IFN-γ, tumor 
necrosis factor (TNF)-α, IFN-γ-induced (IP)-10 (C-X-C motif 
chemokine, CXCL10), monocyte chemoattractant protein 
(MCP)-1 (chemokine ligand 2, CCL2), and sCD40L. Next, 25 
μL specimens of samples and capture beads conjugated with 
specific antibodies were mixed and incubated with detection 
antibodies. The fluorescence of each complex was acquired us-
ing a FACS Verse flow cytometer (BD Biosciences) and ana-
lyzed using the FCAP ArrayTM software (BD Biosciences). The 
values of negative controls were subtracted from those induced 
by each antigen (Supplementary Fig. 2, only online).
 
Statistical analysis
Data were analyzed using Prism 6 (GraphPad Software, La Jol-
la, CA, USA). Differences among the study groups of cytokine/
chemokine production were compared using the Mann-Whit-
ney U test or Kruskal-Wallis one-way analysis of variance test 
with Dunn’s multiple comparison. Values of *p<0.05, **p<0.01, 
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***p<0.001 were considered to be significant. The diagnostic 
accuracies of antigen-specific cytokine/chemokine features 
were assessed by the analysis of the area under the receiver op-
erating characteristic curves (AUCs). Cut-off values of each an-
alyte for the estimation of sensitivity and specificity were select-
ed based on Youden’s index.29
RESULTS
Analysis of sequences of M. tb Beijing/K-derived 
antigen
MTBK24820 is a PPE39 protein identified from M. tb Beijing/K 
strain, which consists of 622 amino acids. Based on sequence 
analyses on MTBK_24820 (BLAST search request identifica-
tion no. S3HGJHAB015), a rate of about 60% for similarity was 
observed in the N-terminus of MTBK_24820 (259 amino acids) 
on alignment with a portion of PPE42, which has been tested 
as a new TB vaccine in clinical trials (Fig. 2).30 Its sequences in 
the N-terminus region are similar with sequences of M. bovis 
BCG as well (Fig. 2). However, most sequences of MTBK_24820 
were disrupted or varied in M. bovis BCG. The protective effi-
cacy of MTBK_24820 in mice infected with M. tb may be asso-
ciated with the homologous sequences in the vaccine candi-
date of TB or the only existing TB vaccine, M. bovis BCG.17
Immune signature in response to MTBK_24820 in 
active TB, LTBI, and controls 
Among the 17 analytes tested, three analytes (CXCL10, IL-6, 
and IFN-α) identified M. tb infection or differentiated disease 
status (active TB vs. LTBI) in response to MTBK_24820 antigen 
(Figs. 3 and 4). MTBK_24820 did not differentiate among the 
study groups measuring the representative cytokine IFN-γ pro-
duction (p>0.05) (Fig. 3A). However, active TB disease was clearly 
distinguished by CXCL10 (p<0.001) (Fig. 3B). MTBK_24820-
specific CXCL10 responses also differentiated between healthy 
subjects and LTBI (p<0.05) (Fig. 3B). MTBK_24820 stimulation 
induced significantly higher IL-6 production in active TB pa-
tients than the healthy controls (p<0.01) (Fig. 3C). No significant 
difference in TNF-α responses was observed among the groups 
(p>0.05) (Fig. 3D). The MTBK_24820-specific IFN-α responses 
were significantly higher in active TB patients than in healthy 
controls (p<0.05) (Fig. 4A), and the IFN-α responses were dif-
ferent between active TB and LTBI in response to MTBK_24820 
(p<0.01) (Fig. 4A). The proportion of IFN-α responders was 
about three-fold higher among active TB cases than in healthy 
subjects (p<0.05) (Fig. 4B). 
Diagnostic value of MTBK_24820 in cytokine/ 
chemokine production 
In response to MTBK_24820, CXCL10, IL-6 and IFN-α produc-
tion differentiated between active TB and healthy controls or 
between active TB and LTBI (Figs. 3 and 4). All of the analytes 
involved in distinguishing between study groups demonstrated 
sufficient diagnostic accuracy (0.55<AUC<0.65) (Table 1). The 
sensitivities and specificities for detecting M. tb infection were 
increased to 65.3% and 95.4% by the combination of CXCL10, 
IL-6, and IFN-α responses in MTBK_24820 stimulation (Table 
2). Among the discriminative markers for disease status (ac-
tive TB vs. LTBI), IFN-α had much higher sensitivity and speci-
ficity with combined responses with CXCL10, when compared 
with single cytokine responses (Table 2). 
Immune signature depending on AFB staining results 
and Beijing/K genotyping
In this study, the majority of TB patients did not have positive 
AFB smear results; only 15 of the 52 TB patients enrolled were 
positive by AFB smear tests. M. tb growth was further confirmed 
by culture in 40 patients (Fig. 1). Of the 37 AFB smear negative 
patients, about 62% (23/37) of the patients showed positive 
responses to CXCL10, IL-6, or/and IFN-α upon MTBK_24820 
stimulation (data not shown). Based on molecular genotyping, 
the Beijing types accounted for 68% (19/28 tested), and most 
isolates (14/19) were revealed as belonging to the Beijing/K 
strain. 
Fig. 2. Sequence homology between M. tb Beijing/K-derived MTBK_24820 and corresponding sequences in vaccine candidate antigens. Amino acid 
sequences of MTBK_24820 were highly conserved with equivalent sequences in M. bovis BCG, and PPE42, respectively. The asterisk (*) represents 
identical amino acids between the antigens and comparing sequences in other strains. M. tb, Mycobacterium tuberculosis.
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Insufficient accuracy of current TB diagnostics and variable 
efficacy of the BCG vaccine suggest a need for the develop-
ment of better strategies for identifying relevant biomarkers in 
TB. Geographically, dominant strains of M. tb have been con-
sidered as sources of new vaccine components, and recent de-
velopments achieved with highly sensitive multiplex detection 
technology have provided means with which to measure a 
number of analytes in limited volumes of a clinical sample. Us-
ing this multiplex detection technology in this study, we assessed 
host immune responses to antigen derived from Beijing/K 
strains which are hyper-virulent and responsible for TB out-
breaks in South Korea. CXCL10, IL-6, and IFN-α were revealed 
as biomarker candidates among the 17 cytokines and chemo-
kines tested. Each cytokine response had sufficient diagnostic 
values (AUC=0.59–0.63), and the sensitivity of single cytokine 
detection was increased with one or two additional cytokine 
combinations with the maintenance of high specificity. 
The protective efficacy of MTBK_24820 in our previous study 
was strengthened by its sequential similarity with PPE42,17 
which has been successfully tested in phase II clinical trials of 
TB vaccines:30,31 specifically, ID93 adjuvant with GLA-SE is a 
subunit vaccine including PPE42 and Esx proteins. Its safety, 
immunogenicity, and preliminary efficacy in preventing TB 
infection were confirmed in M. tb Beijing/K-strain-infected 
mice in a previous study.32 In this study, MTBK_24820-specific 
CXCL10, IL-6, and IFN-α differentiated M. tb infection from 
healthy controls, and active TB from LTBI. This suggests that 
MTBK_24820 may be utilized as a diagnostic antigen, as well as 
a vaccine candidate. 
From the time of infection to active disease progression, 
Fig. 3. Immune profiles of MTBK_24820-specific cytokine/chemokine responses in diagnostic groups. (A) IFN-γ, (B) CXCL10, (C) IL-6, and (D) TNF-α 
were measured in response to MTBK_24820 in active TB (n=52), LTBI (n=31), and healthy control (n=65) groups. (B and C) Significantly higher CXCL10 
and IL-6 responses were also found in active TB patients than in the healthy controls in response to MTBK_24820. Disease status (active TB vs. LTBI) 
was differentiated by MTBK_24820-specific CXCL10. (A and D) IFN-γ and TNF-α responses were not significantly changed in the three groups, com-
pared with other cytokines. The horizontal lines represent medians (*p<0.05, **p<0.01, ***p<0.001; Kruskal-Wallis and Dunn’s multiple comparison 
tests). HC, healthy control; LTBI, latent TB infection; TB, tuberculosis; IFN, interferon; IL, interleukin; CXCL10, C-X-C motif chemokine; TNF, tumor ne-
crosis factor.
794
M. tb Beijing/K Strain-Specific Immune Signatures
https://doi.org/10.3349/ymj.2020.61.9.789
many different cytokines and chemokines are released by im-
mune cells and play roles in protecting against M. tb through 
both innate and adaptive immunity. In response to M. tb in-
fection, TNF-α is secreted primarily by alveolar macrophages 
and initiates innate cytokine/chemokine responses with IL-6 
and type I IFN, while phagocyte activation during early infec-
tion induces adaptive immunity.33 After the M. tb antigen is ex-
pressed by antigen-presenting cells, IFN-γ, which is expressed 
on M. tb-specific T-cells, activates macrophages and contrib-
utes to granuloma formation. CXCL10 is also expressed on M. 
tb-specific T-cells and plays a role in the early recruitment of 
T-cells to the lungs, resulting in granuloma formation.33 IFN-α, 
which belongs to the type I IFN category, is induced by M. tb-
infected macrophages.34,35 Although controversial, a role for 
IFN-α in TB has been reported in the literature. IFN-α expres-
sion was previously shown to be related to strain virulence: the 
messenger RNA expression of IFN-α was significantly higher 
in the lungs of hypervirulent HN878-infected mice than the 
H37Rv strain-infected, whereas the downregulation of IFN-γ 
and TNF-α, which are related to Th1 immunity, was observed.36 
Additional treatment with purified IFN-α/β increased lung 
bacterial burden with reduced survival, and induction of type 
I IFNs in relation to hypervirulent strains caused failure of Th1 
type immunity.36 On the other hand, intramuscular BCG vac-
cination together with IFN-α boosting has been shown to elicit 
a reduction in bacterial load, as well as IFN-γ, IL-12, TNF-α, and 
IL-17 responses.37 In this study, the Beijing/K-specific IFN-α re-
sponses were significantly higher in TB patients than subjects 
with LTBI, suggesting that IFN-α may be more closely associ-
ated with pathogenicity than protection in relation to the Bei-
jing/K strain. Several individuals in the healthy and LTBI groups 
showed positive IFN-α responses; the immune follow-up of 
these individuals might further reveal the pathogenic or protec-
tive role of IFN-α. 
Besides the Beijing/K-derived antigen, we also tested M. tb 
PPD and heparin-binding haemagglutinin (HBHA) proteins 




































Fig. 4. IFN-α production induced by MTBK_24820 in diagnostic groups. (A) MTBK_24820 elicited significantly higher IFN-α responses in active TB pa-
tients than in healthy controls. (B) The proportions of IFN-α responders to MTBK_24820 are represented in each group. The horizontal lines indicate 
medians (*p<0.05, **p<0.01, ***p<0.001; Kruskal-Wallis and Dunn’s multiple comparison tests). HC, healthy control; LTBI, latent TB infection; TB, tuber-
culosis; IFN, interferon. 
Table 2. Improved Diagnostic Accuracy Achieved by Combining Detec-























TB, tuberculosis; LTBI, latent TB infection; IFN, interferon; IL, interleukin; 
CXCL10, C-X-C motif chemokine.
Table 1. Diagnostic Accuracy of MTBK_24820-Specific Immune Responses 
Antigen Group Analyte Sensitivity (%) Specificity (%) Cut-off (pg/mL) AUC (95% CI)
MTBK_24820



























AUC, area under the curve; CI, confidence interval; TB, tuberculosis; LTBI, latent TB infection; IFN, interferon; IL, interleukin; CXCL10, C-X-C motif chemokine.
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kine responses to these antigens showed significant differences 
among the groups. All analytes were present at high concen-
trations in all groups (Supplementary Fig. 3, only online). This 
may due to cross-reactivity with M. bovis BCG in South Korea 
where BCG vaccination is received by >97% of the population. 
M. tb PPD and HBHA-induced cytokines including IFN-γ might 
differentiate between active TB and LTBI or healthy controls 
in countries where BCG vaccination is rare,38,39 whereas the an-
tigens cannot be used as diagnostics in populations with uni-
versal BCG vaccination. The antigens might be useful for con-
firming the immunogenicity of BCG vaccination rather than 
the diagnosis of TB in this context. 
In this study, about 23% of active TB cases were probable TB 
without M. tb identification by culture. Active TB was diagnosed 
from clinical and other diagnostic findings in the culture-nega-
tive patients; however, the possibility of misdiagnosis may ex-
ist, irrespective of the effort made to classify. In addition, QFT-
GIT tests were not performed for diagnosis of active TB, which 
limits the diagnostic efficacy between different testing meth-
ods using the Beijing/K and QFT-GIT antigens. 
Although the sensitivity and specificity of the detection 
should be improved, multi-cytokine signatures to Beijing/K an-
tigens may accelerate the discovery of improved diagnostics and 
new vaccine components in places where the Beijing/K and Bei-
jing/K-homologous strains of M. tb are endemic. This would 
also help with the early diagnosis in AFB smear-negative TB 
patients prior to confirmation with M. tb in culture. Continuous 
efforts for finding biomarkers using predominant M. tb strains 
should be made in cohorts with drug-resistance and outbreaks 
associated with the Beijing/K strain infection.  
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